Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects

International Clinical Psychopharmacology

Volumn 20, Issue 6, 2005, Pages 335-338

  Perquin, Lowijs N M ^a,b  

^a Psychiatric Center   (Netherlands)

^b Valeriuskliniek   (Netherlands)

Author keywords

Extrapyramidal side effects; Schizophrenia; Sertindole; Tardive akathisia; Tardive dyskinesia; Tardive dystonia

Indexed keywords

BIPERIDEN; BROMPERIDOL; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PERPHENAZINE; SERTINDOLE; TETRABENAZINE; ZUCLOPENTHIXOL;

ADULT; AGGRESSION; AKATHISIA; ARTICLE; CASE REPORT; DRUG EFFECT; DRUG SUBSTITUTION; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HALLUCINATION; HOSPITAL ADMISSION; HUMAN; MALE; MOTOR DYSFUNCTION; NOSE CONGESTION; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLOPENTHIXOL; FEMALE; HALOPERIDOL; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; SCHIZOPHRENIA; TIME FACTORS;

EID: 26944455929     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200511000-00010     Document Type: Article

References (22)

1. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
2. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J (1985). Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35:73-77.
3. Casey DE (2004). Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65 (suppl 9):25-28.
4. Daniel DG, Wozniak P, Mack RJ, McCarthy BG (1998). Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 34:61-69.
5. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA (1998). Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18:477-481.
6. Eckardt L, Breithardt G, Haverkamp W (2002). Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 300:64-71.
7. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2004). A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65:696-701.
8. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Department of Health, Education and Welfare.
9. Hale A, Azorin JM, Kasper S, Maier W, Syvalahti E, van der Berght M, et al. (2000). Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 4:55-62.
10. Hogarty GE (1993). Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 54 (suppl):18-23.
11. Kasper S, Quiner S, Pezawas L (1998). A review of the benefit: risk profile of sertindole. Int J Psychiatry Clin Pract 2 (suppl 2):S59-S64.
12. Labelle A, Bourget D, Boulay LJ, Ellis J, Tessier P (2002). Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. J Clin Psychopharmacol 22:545-553.
13. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003). Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209-1222.
14. Loonen AJ, Doorschot CH, van Hemert DA, Oostelbos MC, Sijben AE (2000). The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. Int J Neuropsychopharmacol 3:285-296.
15. Moore N (2002). Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psychiatry Clin Pract 6 (suppl 1): S3-S9.
16. Perquin L, Steinert T (2004). A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 18 (suppl 2):19-30.
17. Sacchetti E, Valsecchi P (2003). Quetiapine, clozapine and olanzapine in the treatment of tardive dyskinesia. J Clin Psychopharmacol 18:357-359.
18. Schwartz M, Hocherman S (2004). Antipsychotic-induced rabbit syndrome: epidemiology, management and pathophysiology. CNS Drugs 18:213-220.
19. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree B (1996). A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 124:168-175.
20. Webster DD (1968). Critical analysis of the disability in Parkinson's disease. Mod Treat 5:257-282.
21. Wirshing WC (2001). Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 62 (suppl 21):15-18.
22. Zimbroff D, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak RJ, et al. (1997). Controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 154:782-791.